ALS is characterized by a progressive decline in motor function due to degeneration of motor neurons.
Key Differences from Other Diseases:
- Unlike multiple sclerosis, ALS does not relapse or exacerbate; it progressively worsens.
- Individuals lose the ability to speak, move, walk, and eventually breathe.
Pathophysiology
Degeneration occurs in the gray matter of the spinal cord and lower cranial nerves.
Loss of motor neurons leads to inability to send electrical and chemical messages to muscles.
Results in:
- Muscles failing to activate, leading to progressive paralysis.
- Characteristics of the disease include difficulty speaking, moving, becoming wheelchair-bound, and ultimately death mainly from respiratory failure.
Onset and Demographics
Most common onset between ages 40-70, affecting males more than females.
Survival Rates:
- Death can occur within 3 to 10 years after onset.
- Progression varies significantly among individuals.
- Average life expectancy post-diagnosis is often 2-5 years.
Symptoms and Manifestations
Initial symptoms include:
- Weakness in voluntary muscles, especially in the extremities.
- Muscle cramps and spasms.
- Difficulty swallowing (dysphagia) and choking.
- Progressive cognitive impairment without affecting intellect.
Late-stage symptoms include:
- Complete dependency on caregivers.
- Inability to eat, speak, or breathe without assistance.
- Pain due to muscle cramps.
Diagnosis
No definitive laboratory test exists for ALS.
Diagnosis usually involves:
- Electromyography (EMG) to assess muscle electrical activity.
- Ruling out other conditions such as multiple sclerosis and myasthenia gravis.
Treatment and Management
Currently no cure for ALS; only symptom management.
Riluzole and edaravone are medications believed to slow progression in some patients, though not commonly included in nursing exams.
Importance of advance care planning for end-of-life wishes:
- Living wills and power of attorney are crucial as the patient deteriorates.
Frequent care requirements as the disease progresses.
Guillain-Barré Syndrome (GBS)
GBS is an immune-mediated disease affecting peripheral nerves, possibly following infections.
Seasonal Changes:
- Symptoms typically appear 2-4 weeks after preceding infections such as gastroenteritis.
Pathophysiology
Characteristic changes include:
- Demyelination and inflammation of nerve roots leading to nerve compression.
Symptoms start with:
- Ascending paralysis, typically beginning in the lower extremities and moving upward.
- Other autonomic symptoms may occur, like bowel and bladder dysfunction.
Symptoms and Progression
Symptoms can include:
- Weakness in extremities, numbness, and tingling.
- Muscle pain, especially at night.
Sequences of phases:
- Acute phase (onset of symptoms).
- Static phase (when symptoms plateau).
- Rehabilitation phase (gradual recovery).
Peak symptoms generally at two weeks, may take longer for recovery but significant recovery in most cases is expected.
Diagnosis
Difficult due to nonspecific symptoms, often mistaken for other conditions (e.g., diabetes).
Tests used:
- CSF analysis may show elevated protein levels.
- Electromyography to assess muscle activity.
Treatment
Supportive care is the mainstay of treatment, with plasmapheresis for severe cases.
Recovery rates are generally high, with most patients regaining full function within a year.
Huntington's Disease
A genetic, progressive neurological disorder marked by chorea and cognitive decline.
Key Characteristics
Symptoms typically become evident between the fourth and fifth decades of life but can appear earlier.
Death usually occurs 15-25 years post-diagnosis, primarily due to neurologic degeneration.
Symptoms
Symptoms include:
- Chorea (abnormal movements), emotional disturbances, and cognitive decline.
- Patients have a 50% chance of passing the disorder onto offspring.
- Neurodegenerative effects lead to loss of coordination and the inability to move independently.
Treatment
Valbenazine for managing involuntary movements; supportive therapies.
Myasthenia Gravis (MG)
An autoimmune disease leading to grave muscle weakness affecting voluntary muscles.
The disease affects ocular muscles leading to diplopia and ptosis.
Key Symptoms
Muscle weakness increases with activity and improves with rest.
Ocular symptoms often precede generalized weakness.
Diagnosis
Based on clinical presentation, symptom patterns, and confirming the presence of autoantibodies against acetylcholine receptors.
Treatment
Main treatments include anticholinesterase medications:
- Neostigmine and pyridostigmine, which prevent acetylcholine breakdown at neuromuscular junctions.
Plasmapheresis during myasthenic crisis, which can be life-threatening due to respiratory failure.
Management Strategies
Schedule patient's activities to allow for rest periods optimizing muscle function throughout the day.
Recognize signs of myasthenic and cholinergic crises, which require immediate medical attention.